ATE264322T1 - Anti-tumor dihydrochinazolindervate - Google Patents

Anti-tumor dihydrochinazolindervate

Info

Publication number
ATE264322T1
ATE264322T1 AT00905212T AT00905212T ATE264322T1 AT E264322 T1 ATE264322 T1 AT E264322T1 AT 00905212 T AT00905212 T AT 00905212T AT 00905212 T AT00905212 T AT 00905212T AT E264322 T1 ATE264322 T1 AT E264322T1
Authority
AT
Austria
Prior art keywords
tumor
dihydroquinazoline derivatives
dihydroquinazoline
derivatives
formulawhere
Prior art date
Application number
AT00905212T
Other languages
English (en)
Inventor
Lorraine Skelton
Vassilis Bavetsias
Ann Jackman
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE264322T1 publication Critical patent/ATE264322T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00905212T 1999-02-24 2000-02-24 Anti-tumor dihydrochinazolindervate ATE264322T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9904275.6A GB9904275D0 (en) 1999-02-24 1999-02-24 Anti-cancer compounds
PCT/GB2000/000655 WO2000050417A1 (en) 1999-02-24 2000-02-24 Anti-cancer dihydroquinazoline derivatives

Publications (1)

Publication Number Publication Date
ATE264322T1 true ATE264322T1 (de) 2004-04-15

Family

ID=10848434

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905212T ATE264322T1 (de) 1999-02-24 2000-02-24 Anti-tumor dihydrochinazolindervate

Country Status (11)

Country Link
US (1) US6699861B1 (de)
EP (1) EP1155012B1 (de)
JP (1) JP2002537391A (de)
AT (1) ATE264322T1 (de)
AU (1) AU772670B2 (de)
CA (1) CA2364708A1 (de)
DE (1) DE60009868T2 (de)
DK (1) DK1155012T3 (de)
ES (1) ES2219308T3 (de)
GB (1) GB9904275D0 (de)
WO (1) WO2000050417A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297701B2 (en) 2001-08-31 2007-11-20 Btg International Limited Anti-cancer cyclopenta [G]quinazoline compounds
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003020300A1 (en) 2001-08-31 2003-03-13 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
JP2005501887A (ja) * 2001-09-05 2005-01-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 癌の処置における組成物およびその使用
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
EA201291302A1 (ru) 2010-07-19 2013-09-30 Оникс Фармасьютикалз, Инк. Синтез циклопентахиназолинов
JP6038792B2 (ja) * 2010-09-03 2016-12-07 フォーマ ティーエム， エルエルシー． 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
IN2015MN00002A (de) 2012-07-09 2015-10-16 Lupin Ltd
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031237B1 (de) 1979-12-19 1984-10-17 National Research Development Corporation Chinazolinderivate, Verfahren zu ihrer Herstellung, sie enthaltende Zusammensetzungen und ihre Verwendung als Anti-Krebs-Mittel
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8707053D0 (en) 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
GB8809978D0 (en) 1988-04-27 1988-06-02 Ici Plc Anti-tumour agents
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
IL98167A0 (en) * 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
GB9105771D0 (en) 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
GB9223352D0 (en) 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds

Also Published As

Publication number Publication date
EP1155012A1 (de) 2001-11-21
DK1155012T3 (da) 2004-08-09
CA2364708A1 (en) 2000-08-31
JP2002537391A (ja) 2002-11-05
ES2219308T3 (es) 2004-12-01
AU772670B2 (en) 2004-05-06
DE60009868D1 (en) 2004-05-19
US6699861B1 (en) 2004-03-02
GB9904275D0 (en) 1999-04-21
DE60009868T2 (de) 2005-04-21
AU2683800A (en) 2000-09-14
EP1155012B1 (de) 2004-04-14
WO2000050417A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
NO173138C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-(3-polycykloalkyloksy-4-alkoksyfenyl)-heksahydro-2-pyrimidinon-derivater
DE69425162D1 (de) 4,5-diaryloxazol-derivate
EP0638567A4 (de) Adenosin-aufnahme inhibitoren.
ES8704485A1 (es) Un procedimiento para la preparacion de derivados de piperazina 1,4-disustituidos.
MY130908A (en) Benzenesulfonamide derivative and the process for preparing thereof
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
NO940737L (de)
EP0254259A3 (de) p-Aminophenol-Derivate
DE60009868T2 (de) Anti-tumor dihydrochinazolindervate
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
ATE197401T1 (de) Chinazolinon-arzneimittel sowie deren verwendung
MXPA02006329A (es) 8-arilquinolinas sustituidas que son inhibidores de fosfodiesterasa-4.
HUP9802290A2 (hu) Pirrolszármazékok és az azokat tartalmazó gyógyászati kompozíciók
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
CA1273942C (en) Derivatives of imidazole, their preparation and utilisation, and pharmaceutical compositions containing these derivatives
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
DK160098C (da) Tricycliske oxindolcarboxamid-derivater
MY113427A (en) Anti-neurodegeneratively active 10-aminoaliphatyl- dibenz [b,f] oxepines
BG101601A (bg) Фармацевтични пиперазинови производни
TW324009B (en) Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor
ES2093091T3 (es) Derivado de glutation.
HUP9904594A2 (hu) Piperazinoszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9900580A2 (hu) Vírusölő hatású 2-amino-5,6-diklór-benzimidazol-származékok
ES8707226A1 (es) Procedimiento para preparar derivados de (dihidro-4, 5-1h-imidazolil-2)-2-didrido-2,3-indol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155012

Country of ref document: EP

REN Ceased due to non-payment of the annual fee